Nanobiotix Unveils Phase 1 Data on NSCLC Therapy

Nanobiotix has announced the completion of the dose escalation part of its Phase 1 study on NBTXR3, intended for patients with locally advanced non-small cell lung cancer (NSCLC). Data highlights include favorable safety results and established injection feasibility in 12 patients. This study focuses on patients who have previously undergone treatment without success.

Initial survival data shows a 12-month local progression-free survival rate of 64% and an overall survival rate of 83% for the same period. These promising early results support the potential benefits of NBTXR3 as a novel therapeutic approach in this patient group.

NBTXR3, a radioenhancer, was released by Nanobiotix to Johnson & Johnson in 2023 and is further developed globally. The study's next steps involve expanding the trials, with five out of twelve patients injected so far in this phase.